Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mologen To Pursue Combinations Only After Lefitolimod’s Solo IMPALA Failure

Executive Summary

Mologen’s CEO tells Scrip the German biotech will only pursue combination studies in future after its lead candidate lefitolimod failed as a monotherapy in a pivotal trial treating metastatic colorectal cancer patients.

You may also be interested in...



InDex's Lead TLR9 Agonist Shows Promise In Ulcerative Colitis

A Toll-like receptor-9 agonist under development by Sweden’s InDex Pharmaceuticals showed encouraging clinical responses in top-line results in patients with active ulcerative colitis not responding to other agents. Its novel mechanism of action and relatively benign side effect profile makes it a prime candidate to combine with biologic agents.

Getting Its ACT Together: EXACT-Tx Raises NOK155m

EXACT-Tx will use funds from a NOK155m private placing to harness ultrasound in precision therapeutic targeting across a variety of indications and product classes.

Newly Launched Eir Ventures To Target ‘Early Nordic Opportunities’

The Nordic region’s vibrant life sciences ecosystem will be the chief focus for newly created Eir Ventures, a strategic partnership and investment company.  

Topics

Related Companies

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel